Unlock instant, AI-driven research and patent intelligence for your innovation.

Transaminase mutant and its application in the preparation of sitagliptin intermediate

A mutant and transaminase technology, applied in the field of recombinant genetically engineered bacteria and recombinant enzymes, can solve the problems of high conversion rate of raw materials, expensive catalyst, high yield, etc., and achieve the effect of high stereoselectivity

Active Publication Date: 2021-07-27
ZHEJIANG UNIV OF TECH +2
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008] The present invention aims at the defects (poor stereoselectivity, expensive catalyst, difficult recovery of solvent, etc.) existing in the existing production process of sitagliptin intermediate, and provides a transaminase mutant, coding gene, recombinant carrier, recombinant Genetically engineered bacteria, and the application of asymmetric transamination to obtain sitagliptin or sitagliptin ester intermediates, the method has high conversion rate of raw materials, low production cost and high yield

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Transaminase mutant and its application in the preparation of sitagliptin intermediate

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0028] Example 1: Amplification of transaminase gene MbTA

[0029] According to the transaminase gene sequencing information from Mycolicibacterium included in Genbank, the total genomic DNA of the transaminase of Mycolicibacterium was extracted with a rapid nucleic acid extraction instrument, and the genomic DNA was used as a template, and primer 1 (ATGGGCATCGATACC), primer 2 (GTAGCAGATATCTTCGA) for PCR amplification. PCR reaction system (total volume 50 μL): 5 μL of 10×Pfu DNA Polymerase Buffer, 1 μL of 10 mM dNTP mixture (2.5 mM each of dATP, dCTP, dGTP and dTTP), 1 μL of cloning primer 1 and primer 2 each at a concentration of 50 μM, 1 μL of genomic DNA , Pfu DNA Polymerase 1μL, nucleic acid-free water 40μL.

[0030] Using BioRad PCR instrument, PCR reaction conditions: pre-denaturation at 95°C for 5min, denaturation at 95°C for 30s, annealing at 65°C for 45s, extension at 72°C for 1min, a total of 30 cycles, and finally extension at 72°C for 10min.

[0031] The PCR reac...

Embodiment 2

[0032] Embodiment 2: Construction of recombinant Escherichia coli BL21 / pET28b-MbTA

[0033] Primer 3 (CCG) was designed according to the MbTA gene sequence in Example 1 GAATTC GGTATCGACACCGGTACCTC), primer 4 (TTGGG ATCCGT ACTGGATAGCTTCGATCAGC)), and EcoR I and BamH I restriction enzyme sites (underlined) were introduced into primer 3 and primer 4, respectively. Under the initiation of primer 3 and primer 4, high-fidelity Pfu DNA polymerase was used to amplify, and the recombinant plasmid pMD18-T-MbTA was used as a template (obtained in Example 1) to obtain the MbTA gene sequence. After sequencing, EcoR I and The amplified fragment was treated with BamH I restriction endonuclease (TaKaRa), and the fragment was ligated with the commercial vector pET28b (Invitrogen) treated with the same restriction endonuclease using T4 DNA ligase (TaKaRa) to construct Expression vector pET28b-MbTA. The constructed expression vector pET28b-MbTA was transformed into Escherichia coli BL21(DE3...

Embodiment 3

[0034] Example 3: Induced expression of aminotransferase (MbTA)

[0035] The recombinant Escherichia coli BL21(DE3) / pET28b-MbTA obtained in Example 2 was inoculated into LB liquid medium containing 50 μg / ml kanamycin resistance, cultivated at 37° C. for 12 hours at 200 rpm, and then treated with 1% (v / v) The inoculum is inoculated into fresh LB liquid medium containing 50 μg / ml kanamycin resistance, cultured at 37°C and 150 rpm until the OD 600 of the bacteria reaches 0.6-0.8, and the final concentration of 0.1 mM IPTG is added After induction culture at 28°C for 12h, centrifuge at 5000rpm at 4°C for 25min, discard the supernatant, collect the precipitate, and obtain the recombinant Escherichia coli BL21 / pET28b-MbTA wet cell containing the expression recombinant plasmid. The bacterium can be used directly as a biocatalyst or for protein purification.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a transaminase mutant and its application in the preparation of a sitagliptin intermediate. The mutant is that the tyrosine at the 74th position of the amino acid sequence shown in SEQ ID NO: 2 is replaced with proline, and the 228th position of the amino acid sequence is replaced with proline. Glutamic acid at position 2 is replaced by aspartic acid, leucine at position 254 is replaced by alanine, and methionine at position 290 is replaced by threonine. In the present invention, the wet thallus or pure enzyme obtained by fermenting and cultivating engineering bacteria containing transaminase mutant coding genes is used as a biocatalyst, and the sitagliptin intermediate precursor ketone or latent chiral carbonyl compound is used as a substrate to prepare sitagliptin Tin intermediate or sitagliptin ester intermediate; the total yield of the method of the present invention is about 82%, and the product e.e. value reaches 99%.

Description

[0001] (1) Technical field [0002] The present invention relates to the field of biochemical technology, specifically, a method for preparing an optically pure sitagliptin intermediate of transaminase and its mutant enzyme, including transaminase, mutant, coding gene, recombinant vector containing the gene, the Recombinant genetically engineered bacteria and recombinase obtained by transformation of the recombinant vector, and applications. [0003] (2) Background technology [0004] Sitagliptin (sitagliptin) was researched and developed by American Merck Company and Codexis Company. It is the first dipeptidyl peptidase-IV (DPP-IV) inhibitor approved by FDA for the treatment of type Ⅱ diabetes. Sitagliptin can increase the secretion of insulin in a blood glucose-dependent manner, and has a relatively moderate hypoglycemic effect, without causing hypoglycemia, and without side effects such as weight gain, nausea, and vomiting. The trade name of sitagliptin is Januvia, which ha...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C12N9/10C12N15/54C12N1/21C12P41/00C12P17/12C12P13/00C12R1/19
CPCC12N9/1096C12P41/006C12P17/12C12P13/001C12Y206/01C12N1/20C12N15/70C12N2800/101C12P17/182C12Y206/01018
Inventor 柳志强程峰张晓健贾东旭郑裕国何人宝金逸中邵鸿鸣林娇华张峰
Owner ZHEJIANG UNIV OF TECH